International Drug Development

International Drug Development (IDD) is a French pharmaceutical and biotechnology company that provides end-to-end support for drug development, regulatory strategy, and commercialization. Headquartered in Paris with a specialized biotech division in Lyon, the company focuses on the development of monoclonal antibodies for oncology and hematology, as well as niche generics for global markets. IDD has established a strong track record of licensing its proprietary assets to major pharmaceutical partners, including the sale of its DR5 antibody program to Genmab and the licensing of its anti-CD19 candidate to Enzene Biosciences. Additionally, the company operates the Bio Valys Pharma platform, which serves as an autonomous pharmaceutical hub for marketing and distributing essential medicines across Europe. Through its multidisciplinary team, IDD assists global sponsors in navigating complex regulatory landscapes from early development to market access.